Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | February 24, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date February 24, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,119 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Grant · Acquired 4,475 · Balance 124,119 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-24 · Disposition to issuer · Disposed 4,475 · Balance 0 F1: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 25, 2026 16:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001005544-26-000004 · wk-form4_1772056655.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,475 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 16:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001005544-26-000004 · wk-form4_1772056655.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,119 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 16:40 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001005544-26-000002 · wk-form4_1771623627.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 16:40 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001005544-26-000002 · wk-form4_1771623627.xml · derivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 18:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001628280-25-053877 · wk-form4_1764026210.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 18:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001628280-25-053877 · wk-form4_1764026210.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 16:21 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,200 | $51.55 | $61,860.00 |
DisclosureSEC source: 0001628280-25-044797 · wk-form4_1760127657.xml · nonDerivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.39 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 16:21 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 23,800 | $50.73 | $1,207,374.00 |
DisclosureSEC source: 0001628280-25-044797 · wk-form4_1760127657.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,844 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.12 to $51.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 16:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,588 | $45.01 | $161,495.88 |
DisclosureSEC source: 0001005544-25-000008 · wk-form4_1756497902.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.04. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 16:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,000 | $45.00 | $45,000.00 |
DisclosureSEC source: 0001005544-25-000006 · wk-form4_1756328215.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,232 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 16:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,412 | $45.00 | $63,540.00 |
DisclosureSEC source: 0001005544-25-000004 · wk-form4_1756239595.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,232 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 17:47 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007476 · wk-form4_1740437240.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,369 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 17:47 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007476 · wk-form4_1740437240.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,644 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:50 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007189 · wk-form4_1740174641.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:50 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,296 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007189 · wk-form4_1740174641.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests on February 19, 2026. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,700 | $36.24 | $387,768.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · nonDerivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,275 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $9.13 | $182,600.00 |
DisclosureSEC source: 0001628280-24-047155 · wk-form4_1731446109.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 17:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028281 · tm247055-15_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,886 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. F2 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 17:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028281 · tm247055-15_4seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,975 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027579 · tm247055-7_4seq1.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,252 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027579 · tm247055-7_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,252 Underlying: Common Stock · 8,252 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests on February 22, 2025. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 7,457 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-23-119962 · tm2331055-2_4seq1.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,457 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 2,500 | $28.01 | $70,025.00 |
DisclosureSEC source: 0001104659-23-119962 · tm2331055-2_4seq1.xml · nonDerivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,089 F1 · shares: Represents the number of shares of common stock sold to cover the exercise price of the employee stock options. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,457 | $9.24 | $68,902.68 |
DisclosureSEC source: 0001104659-23-119962 · tm2331055-2_4seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026081 · tm237737-15_4seq1.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Underlying: Common Stock · 3,886 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,293 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026081 · tm237737-15_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 Underlying: Common Stock · 6,293 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:08 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025374 · tm237737-1_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:08 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025374 · tm237737-1_4seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,132 Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,722 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-131398 · tm2233689-1_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,722 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,722 | $7.90 | $68,903.80 |
DisclosureSEC source: 0001104659-22-131398 · tm2233689-1_4seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026875 · tm227622-2_4seq1.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,882 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,847 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026875 · tm227622-2_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,847 Underlying: Common Stock · 6,847 shares Expires 2032-02-22 Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:20 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026109 · tm227492-5_4seq.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:20 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026109 · tm227492-5_4seq.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,731 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:46 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-026927 · tm217706-2_4seq1.xml · derivative · entry 3 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,222 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. F2 · derivative.expiration_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:46 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,365 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026927 · tm217706-2_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 7,365 shares Expires 2031-02-19 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,305 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024891 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,305 Underlying: Common Stock · 9,305 shares Expires 2030-02-21 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,211 | $23.99 | $125,011.89 |
DisclosureSEC source: 0001104659-20-024891 · a4.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,509 F1 · shares: Represents restricted stock unit component of the annual equity compensation to directors. These shares will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:25 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,427 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010795 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 Underlying: Common Stock · 12,427 shares Expires 2029-02-22 Read SEC document |
| April 17, 2018 Filed Feb 8, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GiftCommon Stock | 2,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-014592 · tm235112-4_5seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,250 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 17:48 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,613 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-012894 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,613 Underlying: Common Stock · 8,613 shares Expires 2028-02-23 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:42 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039592 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012173 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.